CN101392239A - 减毒的人-牛嵌合副流感病毒(piv)疫苗 - Google Patents
减毒的人-牛嵌合副流感病毒(piv)疫苗 Download PDFInfo
- Publication number
- CN101392239A CN101392239A CNA2008100985262A CN200810098526A CN101392239A CN 101392239 A CN101392239 A CN 101392239A CN A2008100985262 A CNA2008100985262 A CN A2008100985262A CN 200810098526 A CN200810098526 A CN 200810098526A CN 101392239 A CN101392239 A CN 101392239A
- Authority
- CN
- China
- Prior art keywords
- piv
- genome
- gene
- virus
- chimeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 339
- 208000002606 Paramyxoviridae Infections Diseases 0.000 title claims abstract description 9
- 230000002238 attenuated effect Effects 0.000 title abstract description 125
- 229960005486 vaccine Drugs 0.000 title description 98
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 466
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 132
- 208000015181 infectious disease Diseases 0.000 claims abstract description 105
- 238000000034 method Methods 0.000 claims abstract description 81
- 230000002458 infectious effect Effects 0.000 claims abstract description 56
- 230000002163 immunogen Effects 0.000 claims abstract description 51
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 44
- 239000002157 polynucleotide Substances 0.000 claims abstract description 44
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 44
- 239000000203 mixture Substances 0.000 claims abstract description 37
- 230000003612 virological effect Effects 0.000 claims abstract description 37
- 230000036039 immunity Effects 0.000 claims abstract description 12
- 241000712003 Human respirovirus 3 Species 0.000 claims description 234
- 230000035772 mutation Effects 0.000 claims description 212
- 235000018102 proteins Nutrition 0.000 claims description 124
- 239000002773 nucleotide Substances 0.000 claims description 87
- 125000003729 nucleotide group Chemical group 0.000 claims description 86
- 108090000288 Glycoproteins Proteins 0.000 claims description 79
- 235000001014 amino acid Nutrition 0.000 claims description 61
- 102000003886 Glycoproteins Human genes 0.000 claims description 60
- 210000004027 cell Anatomy 0.000 claims description 48
- 150000001413 amino acids Chemical class 0.000 claims description 45
- 210000002345 respiratory system Anatomy 0.000 claims description 43
- 239000013598 vector Substances 0.000 claims description 43
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 41
- 230000014509 gene expression Effects 0.000 claims description 41
- 239000012634 fragment Substances 0.000 claims description 38
- 230000001681 protective effect Effects 0.000 claims description 38
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 37
- 241000726041 Human respirovirus 1 Species 0.000 claims description 34
- 238000012217 deletion Methods 0.000 claims description 34
- 230000037430 deletion Effects 0.000 claims description 34
- 239000000427 antigen Substances 0.000 claims description 33
- 108091007433 antigens Proteins 0.000 claims description 32
- 102000036639 antigens Human genes 0.000 claims description 32
- 230000036961 partial effect Effects 0.000 claims description 32
- 230000000890 antigenic effect Effects 0.000 claims description 30
- 230000028993 immune response Effects 0.000 claims description 30
- 239000002245 particle Substances 0.000 claims description 28
- 241001559187 Human rubulavirus 2 Species 0.000 claims description 27
- 230000005847 immunogenicity Effects 0.000 claims description 27
- 108020004705 Codon Proteins 0.000 claims description 26
- 108700026244 Open Reading Frames Proteins 0.000 claims description 26
- 229910052698 phosphorus Inorganic materials 0.000 claims description 24
- 230000008859 change Effects 0.000 claims description 23
- 238000013518 transcription Methods 0.000 claims description 23
- 229910052757 nitrogen Inorganic materials 0.000 claims description 22
- 230000035897 transcription Effects 0.000 claims description 22
- 230000012010 growth Effects 0.000 claims description 21
- 108091081024 Start codon Proteins 0.000 claims description 20
- 230000002068 genetic effect Effects 0.000 claims description 20
- 241000712079 Measles morbillivirus Species 0.000 claims description 17
- 230000001105 regulatory effect Effects 0.000 claims description 13
- 239000013604 expression vector Substances 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 230000004044 response Effects 0.000 claims description 8
- 241000711798 Rabies lyssavirus Species 0.000 claims description 7
- 241000711386 Mumps virus Species 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 5
- 101150034814 F gene Proteins 0.000 claims description 5
- 101150008820 HN gene Proteins 0.000 claims description 5
- 230000008030 elimination Effects 0.000 claims description 5
- 238000003379 elimination reaction Methods 0.000 claims description 5
- 108091092724 Noncoding DNA Proteins 0.000 claims description 4
- 241000710929 Alphavirus Species 0.000 claims description 3
- 241000701022 Cytomegalovirus Species 0.000 claims description 3
- 241000711950 Filoviridae Species 0.000 claims description 3
- 241000710831 Flavivirus Species 0.000 claims description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 3
- 101150062031 L gene Proteins 0.000 claims description 3
- 241000713112 Orthobunyavirus Species 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 3
- 239000006166 lysate Substances 0.000 claims description 3
- 101150039660 HA gene Proteins 0.000 claims description 2
- 241000701806 Human papillomavirus Species 0.000 claims description 2
- 101100339442 Human parainfluenza 2 virus HN gene Proteins 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 238000005507 spraying Methods 0.000 claims description 2
- 230000006641 stabilisation Effects 0.000 claims description 2
- 238000011105 stabilization Methods 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims 2
- 108091029795 Intergenic region Proteins 0.000 claims 2
- 230000008485 antagonism Effects 0.000 claims 2
- 241000780272 Mammilla Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108020005038 Terminator Codon Proteins 0.000 claims 1
- 210000003104 cytoplasmic structure Anatomy 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 230000010363 phase shift Effects 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 abstract description 68
- 108010089430 Phosphoproteins Proteins 0.000 abstract description 8
- 102000007982 Phosphoproteins Human genes 0.000 abstract description 8
- 101710181008 P protein Proteins 0.000 abstract description 4
- 101710177166 Phosphoprotein Proteins 0.000 abstract description 4
- 102100034574 P protein Human genes 0.000 abstract description 2
- 241000712005 Bovine respirovirus 3 Species 0.000 description 197
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 174
- 239000002299 complementary DNA Substances 0.000 description 110
- 230000000875 corresponding effect Effects 0.000 description 93
- 230000010076 replication Effects 0.000 description 81
- 101150034575 piv gene Proteins 0.000 description 60
- 238000006467 substitution reaction Methods 0.000 description 59
- 238000000917 particle-image velocimetry Methods 0.000 description 50
- 229940024606 amino acid Drugs 0.000 description 41
- 108020004414 DNA Proteins 0.000 description 37
- 229940125575 vaccine candidate Drugs 0.000 description 33
- 241000282553 Macaca Species 0.000 description 30
- 241000282412 Homo Species 0.000 description 27
- 239000000047 product Substances 0.000 description 27
- 238000007792 addition Methods 0.000 description 26
- 239000013612 plasmid Substances 0.000 description 25
- 108091026890 Coding region Proteins 0.000 description 24
- 125000003275 alpha amino acid group Chemical group 0.000 description 24
- 241000282693 Cercopithecidae Species 0.000 description 23
- 238000003780 insertion Methods 0.000 description 23
- 230000037431 insertion Effects 0.000 description 23
- 241000282560 Macaca mulatta Species 0.000 description 20
- 231100000350 mutagenesis Toxicity 0.000 description 19
- 238000003752 polymerase chain reaction Methods 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 238000000338 in vitro Methods 0.000 description 17
- 238000002703 mutagenesis Methods 0.000 description 17
- 241000288906 Primates Species 0.000 description 16
- 238000004113 cell culture Methods 0.000 description 15
- 101710141454 Nucleoprotein Proteins 0.000 description 14
- 108010067390 Viral Proteins Proteins 0.000 description 14
- 230000029087 digestion Effects 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 230000004048 modification Effects 0.000 description 14
- 238000012986 modification Methods 0.000 description 14
- 238000003757 reverse transcription PCR Methods 0.000 description 14
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 13
- 241001493065 dsRNA viruses Species 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 210000002845 virion Anatomy 0.000 description 13
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 12
- 230000009467 reduction Effects 0.000 description 12
- 241000711408 Murine respirovirus Species 0.000 description 11
- 238000010276 construction Methods 0.000 description 11
- 238000011161 development Methods 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 11
- 230000003053 immunization Effects 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 244000052769 pathogen Species 0.000 description 11
- 230000008707 rearrangement Effects 0.000 description 11
- 238000002741 site-directed mutagenesis Methods 0.000 description 11
- 238000013519 translation Methods 0.000 description 11
- 230000029812 viral genome replication Effects 0.000 description 11
- 238000002649 immunization Methods 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 239000013615 primer Substances 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- 108090000994 Catalytic RNA Proteins 0.000 description 9
- 102000053642 Catalytic RNA Human genes 0.000 description 9
- 108020001507 fusion proteins Proteins 0.000 description 9
- 108091092562 ribozyme Proteins 0.000 description 9
- 230000035945 sensitivity Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 8
- 238000010357 RNA editing Methods 0.000 description 8
- 230000026279 RNA modification Effects 0.000 description 8
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000001086 cytosolic effect Effects 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- 230000003472 neutralizing effect Effects 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 208000023504 respiratory system disease Diseases 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000014621 translational initiation Effects 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- 101710117545 C protein Proteins 0.000 description 6
- 241000712431 Influenza A virus Species 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 6
- 241001559185 Mammalian rubulavirus 5 Species 0.000 description 6
- 101710137500 T7 RNA polymerase Proteins 0.000 description 6
- 108020000999 Viral RNA Proteins 0.000 description 6
- 230000004075 alteration Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 108020001580 protein domains Proteins 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 241000699800 Cricetinae Species 0.000 description 5
- 208000005331 Hepatitis D Diseases 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 230000000120 cytopathologic effect Effects 0.000 description 5
- 210000005220 cytoplasmic tail Anatomy 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- 241000271566 Aves Species 0.000 description 4
- 241000711895 Bovine orthopneumovirus Species 0.000 description 4
- 108091062157 Cis-regulatory element Proteins 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 108091035707 Consensus sequence Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108060003393 Granulin Proteins 0.000 description 4
- 241000617996 Human rotavirus Species 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 241000700618 Vaccinia virus Species 0.000 description 4
- 241000711975 Vesicular stomatitis virus Species 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000004186 co-expression Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000037433 frameshift Effects 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 208000029570 hepatitis D virus infection Diseases 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 229940124590 live attenuated vaccine Drugs 0.000 description 4
- 229940023012 live-attenuated vaccine Drugs 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000005030 transcription termination Effects 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 241000711404 Avian avulavirus 1 Species 0.000 description 3
- 206010006448 Bronchiolitis Diseases 0.000 description 3
- 241000711920 Human orthopneumovirus Species 0.000 description 3
- 208000002979 Influenza in Birds Diseases 0.000 description 3
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 3
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 108010021466 Mutant Proteins Proteins 0.000 description 3
- 102000008300 Mutant Proteins Human genes 0.000 description 3
- 206010033078 Otitis media Diseases 0.000 description 3
- 101150084044 P gene Proteins 0.000 description 3
- 241000282405 Pongo abelii Species 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- 229940031567 attenuated vaccine Drugs 0.000 description 3
- 206010064097 avian influenza Diseases 0.000 description 3
- -1 cationic lipid Chemical class 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 201000010549 croup Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 3
- 231100000221 frame shift mutation induction Toxicity 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000001989 nasopharynx Anatomy 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000005026 transcription initiation Effects 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000712083 Canine morbillivirus Species 0.000 description 2
- 206010011416 Croup infectious Diseases 0.000 description 2
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 2
- 102100023419 Cystic fibrosis transmembrane conductance regulator Human genes 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 101000686777 Escherichia phage T7 T7 RNA polymerase Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108700004031 HN Proteins 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 101710091977 Hydrophobin Proteins 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 2
- 101710085938 Matrix protein Proteins 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 101710127721 Membrane protein Proteins 0.000 description 2
- 101000892448 Neisseria gonorrhoeae Type II restriction enzyme NgoMIV Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 101800004937 Protein C Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 241000711897 Rinderpest morbillivirus Species 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 2
- 101800001700 Saposin-D Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 241000700647 Variola virus Species 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004671 cell-free system Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000004077 genetic alteration Effects 0.000 description 2
- 231100000118 genetic alteration Toxicity 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229940031348 multivalent vaccine Drugs 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 229940124551 recombinant vaccine Drugs 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 230000006490 viral transcription Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- BEJKOYIMCGMNRB-GRHHLOCNSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BEJKOYIMCGMNRB-GRHHLOCNSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- 101150039504 6 gene Proteins 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000702673 Bovine rotavirus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000122205 Chamaeleonidae Species 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 101150097493 D gene Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 101000658547 Escherichia coli (strain K12) Type I restriction enzyme EcoKI endonuclease subunit Proteins 0.000 description 1
- 101000658543 Escherichia coli Type I restriction enzyme EcoAI endonuclease subunit Proteins 0.000 description 1
- 101000658546 Escherichia coli Type I restriction enzyme EcoEI endonuclease subunit Proteins 0.000 description 1
- 101000658530 Escherichia coli Type I restriction enzyme EcoR124II endonuclease subunit Proteins 0.000 description 1
- 101000658540 Escherichia coli Type I restriction enzyme EcoprrI endonuclease subunit Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 101000658545 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Type I restriction enyme HindI endonuclease subunit Proteins 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 101000926057 Human herpesvirus 2 (strain G) Envelope glycoprotein C Proteins 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 238000012218 Kunkel's method Methods 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 101000658548 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) Putative type I restriction enzyme MjaIXP endonuclease subunit Proteins 0.000 description 1
- 101000658542 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) Putative type I restriction enzyme MjaVIIIP endonuclease subunit Proteins 0.000 description 1
- 101000658529 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) Putative type I restriction enzyme MjaVIIP endonuclease subunit Proteins 0.000 description 1
- 241000712045 Morbillivirus Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- JJIHLJJYMXLCOY-BYPYZUCNSA-N N-acetyl-L-serine Chemical compound CC(=O)N[C@@H](CO)C(O)=O JJIHLJJYMXLCOY-BYPYZUCNSA-N 0.000 description 1
- PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 description 1
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241001113283 Respirovirus Species 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 108020005148 Ribonucleic Acid Regulatory Sequences Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241001247927 Rotavirus G1 Species 0.000 description 1
- 241001245603 Rotavirus G2 Species 0.000 description 1
- 241001493038 Rotavirus G4 Species 0.000 description 1
- 206010067470 Rotavirus infection Diseases 0.000 description 1
- 241001533467 Rubulavirus Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000251131 Sphyrna Species 0.000 description 1
- 101001042773 Staphylococcus aureus (strain COL) Type I restriction enzyme SauCOLORF180P endonuclease subunit Proteins 0.000 description 1
- 101000838760 Staphylococcus aureus (strain MRSA252) Type I restriction enzyme SauMRSORF196P endonuclease subunit Proteins 0.000 description 1
- 101000838761 Staphylococcus aureus (strain MSSA476) Type I restriction enzyme SauMSSORF170P endonuclease subunit Proteins 0.000 description 1
- 101000838758 Staphylococcus aureus (strain MW2) Type I restriction enzyme SauMW2ORF169P endonuclease subunit Proteins 0.000 description 1
- 101001042566 Staphylococcus aureus (strain Mu50 / ATCC 700699) Type I restriction enzyme SauMu50ORF195P endonuclease subunit Proteins 0.000 description 1
- 101000838763 Staphylococcus aureus (strain N315) Type I restriction enzyme SauN315I endonuclease subunit Proteins 0.000 description 1
- 101000838759 Staphylococcus epidermidis (strain ATCC 35984 / RP62A) Type I restriction enzyme SepRPIP endonuclease subunit Proteins 0.000 description 1
- 101000838756 Staphylococcus saprophyticus subsp. saprophyticus (strain ATCC 15305 / DSM 20229 / NCIMB 8711 / NCTC 7292 / S-41) Type I restriction enzyme SsaAORF53P endonuclease subunit Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 101150117115 V gene Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940031416 bivalent vaccine Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000002962 chemical mutagen Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000004883 computer application Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical group C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 208000005923 otitis media with effusion Diseases 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- KVMLCRQYXDYXDX-UHFFFAOYSA-M potassium;chloride;hydrochloride Chemical compound Cl.[Cl-].[K+] KVMLCRQYXDYXDX-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000000601 reactogenic effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000017610 release of virus from host Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 238000001629 sign test Methods 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940031351 tetravalent vaccine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 229940126580 vector vaccine Drugs 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 230000008478 viral entry into host cell Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14313499P | 1999-07-09 | 1999-07-09 | |
| US60/143,134 | 1999-07-09 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB008101205A Division CN100402651C (zh) | 1999-07-09 | 2000-06-16 | 减毒的人-牛嵌合副流感病毒(piv)疫苗 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101392239A true CN101392239A (zh) | 2009-03-25 |
Family
ID=22502741
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008100985262A Pending CN101392239A (zh) | 1999-07-09 | 2000-06-15 | 减毒的人-牛嵌合副流感病毒(piv)疫苗 |
| CNB008101205A Expired - Fee Related CN100402651C (zh) | 1999-07-09 | 2000-06-16 | 减毒的人-牛嵌合副流感病毒(piv)疫苗 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB008101205A Expired - Fee Related CN100402651C (zh) | 1999-07-09 | 2000-06-16 | 减毒的人-牛嵌合副流感病毒(piv)疫苗 |
Country Status (12)
| Country | Link |
|---|---|
| EP (3) | EP2019141A3 (enExample) |
| JP (1) | JP4813711B2 (enExample) |
| KR (1) | KR100940776B1 (enExample) |
| CN (2) | CN101392239A (enExample) |
| AT (1) | ATE408693T1 (enExample) |
| BR (1) | BR0013190A (enExample) |
| CA (1) | CA2378661A1 (enExample) |
| DE (1) | DE60040289D1 (enExample) |
| ES (1) | ES2312347T3 (enExample) |
| IL (2) | IL147167A0 (enExample) |
| MX (1) | MXPA01013302A (enExample) |
| WO (1) | WO2001004320A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113322241A (zh) * | 2021-05-14 | 2021-08-31 | 金宇保灵生物药品有限公司 | 一种牛副流感病毒3型病毒株bpiv3-nm及其应用 |
| CN118909958A (zh) * | 2024-07-25 | 2024-11-08 | 中国兽医药品监察所 | 一株牛副流感病毒3型np蛋白杂交瘤细胞株及单抗和在检测抗原中的应用 |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7192593B2 (en) | 1997-05-23 | 2007-03-20 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens |
| MXPA01008108A (es) * | 1999-12-10 | 2004-11-12 | Health | Uso de virus de parainfluenza recombinante (pivs) como vectores para la proteccioncontra la infeccion y enfermedad provocadas por piv y otros patogenos humanos. |
| US6764685B1 (en) | 2000-03-21 | 2004-07-20 | Medimmune Vaccines, Inc. | Recombinant parainfluenza virus expression systems and vaccines |
| AU2001271909A1 (en) * | 2000-07-05 | 2002-01-14 | The Government Of The United States Of America, As Represented By The Department Of Health And Human Services | Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines |
| UA93981C2 (ru) | 2001-01-19 | 2011-03-25 | Вироновативе Б.B. | Вирус, который вызывает заболевание дыхательных путей у чувствительных k этому млекопитающих |
| US8715922B2 (en) | 2001-01-19 | 2014-05-06 | ViroNovative | Virus causing respiratory tract illness in susceptible mammals |
| EP1456398B1 (en) | 2001-11-21 | 2011-05-11 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Recovery of recombinant human parainfluenza virus type 1 (hpivi) from cdna |
| CA2477235A1 (en) | 2002-02-21 | 2003-09-04 | Medimmune Vaccines, Inc. | Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus |
| US7820181B2 (en) | 2002-09-18 | 2010-10-26 | The United States Of America As Represented By The Department Of Health And Human Services | Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens |
| JP2007524372A (ja) | 2003-02-28 | 2007-08-30 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 組換えヒトメタニューモウイルスおよびその使用 |
| CA2523657A1 (en) * | 2003-04-25 | 2005-03-31 | Medimmune Vaccines, Inc. | Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus |
| JP2007525178A (ja) | 2003-04-25 | 2007-09-06 | メッドイミューン バクシーンズ，インコーポレイティド | メタニューモウイルス株、そのワクチン製剤における用途、抗原性配列の発現のためのベクターとしての用途、並びにウイルス増殖方法 |
| KR100999316B1 (ko) | 2003-06-09 | 2010-12-10 | 와이어쓰 엘엘씨 | ｃＤＮＡ로부터의 비분절 네가티브 쇄 ＲＮＡ 바이러스의회수를 위한 개선된 방법 |
| CN107818197B (zh) * | 2017-09-15 | 2021-05-25 | 南京航空航天大学 | 一种基于piv技术的超声速翼型的测力方法和装置 |
| GB201816873D0 (en) * | 2018-10-17 | 2018-11-28 | Imperial Innovations Ltd | Fusion protein |
| CN116676275B (zh) * | 2023-03-17 | 2024-06-07 | 北京赛尔富森生物科技有限公司 | A基因型嵌合腮腺炎病毒株和制备方法及用途 |
| TW202535439A (zh) | 2023-11-17 | 2025-09-16 | 美商賽諾菲巴斯德公司 | 海藻糖疫苗調配物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| GB9200117D0 (en) * | 1992-01-06 | 1992-02-26 | Connaught Lab | Production of recombinant chimeric proteins for vaccine use |
| ATE181112T1 (de) | 1995-08-09 | 1999-06-15 | Schweiz Serum & Impfinst | Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren |
| JPH11513372A (ja) * | 1995-09-22 | 1999-11-16 | コノート ラボラトリーズ リミテッド | パラインフルエンザウイルスの糖タンパクおよびワクチン |
| US5869036A (en) * | 1995-12-08 | 1999-02-09 | St. Louis University | Live attenuated vaccines based on CP45 HPIV-3 strain and method to ensure attenuation in such vaccine |
| EP2112220A3 (en) | 1996-07-15 | 2010-01-06 | The Government of the United States of America, as represented by The Department of Health and Human Services | Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences |
| BR9809456B1 (pt) * | 1997-05-23 | 2011-06-28 | molécula isolada de polinucleotìdeo, composição de célula ou isenta de célula, partìcula de piv infeciosa, atenuada e imunogênica, e, composição imunogênica. |
-
2000
- 2000-06-15 KR KR1020027000325A patent/KR100940776B1/ko not_active Expired - Fee Related
- 2000-06-15 CA CA002378661A patent/CA2378661A1/en not_active Abandoned
- 2000-06-15 CN CNA2008100985262A patent/CN101392239A/zh active Pending
- 2000-06-16 DE DE60040289T patent/DE60040289D1/de not_active Expired - Lifetime
- 2000-06-16 EP EP08164460A patent/EP2019141A3/en not_active Withdrawn
- 2000-06-16 BR BR0013190-3A patent/BR0013190A/pt not_active Application Discontinuation
- 2000-06-16 IL IL14716700A patent/IL147167A0/xx unknown
- 2000-06-16 MX MXPA01013302A patent/MXPA01013302A/es active IP Right Grant
- 2000-06-16 ES ES00941614T patent/ES2312347T3/es not_active Expired - Lifetime
- 2000-06-16 CN CNB008101205A patent/CN100402651C/zh not_active Expired - Fee Related
- 2000-06-16 JP JP2001509524A patent/JP4813711B2/ja not_active Expired - Fee Related
- 2000-06-16 AT AT00941614T patent/ATE408693T1/de not_active IP Right Cessation
- 2000-06-16 WO PCT/US2000/017066 patent/WO2001004320A1/en not_active Ceased
- 2000-06-16 EP EP08164459A patent/EP2019140A3/en not_active Withdrawn
- 2000-06-16 EP EP00941614A patent/EP1194564B1/en not_active Expired - Lifetime
-
2001
- 2001-12-18 IL IL147167A patent/IL147167A/en not_active IP Right Cessation
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113322241A (zh) * | 2021-05-14 | 2021-08-31 | 金宇保灵生物药品有限公司 | 一种牛副流感病毒3型病毒株bpiv3-nm及其应用 |
| CN113322241B (zh) * | 2021-05-14 | 2023-06-13 | 金宇保灵生物药品有限公司 | 一种牛副流感病毒3型病毒株bpiv3-nm及其应用 |
| CN118909958A (zh) * | 2024-07-25 | 2024-11-08 | 中国兽医药品监察所 | 一株牛副流感病毒3型np蛋白杂交瘤细胞株及单抗和在检测抗原中的应用 |
| CN118909958B (zh) * | 2024-07-25 | 2025-02-07 | 中国兽医药品监察所 | 一株牛副流感病毒3型np蛋白杂交瘤细胞株及单抗和在检测抗原中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2019141A2 (en) | 2009-01-28 |
| EP1194564B1 (en) | 2008-09-17 |
| BR0013190A (pt) | 2002-07-16 |
| EP1194564A1 (en) | 2002-04-10 |
| EP2019141A3 (en) | 2009-02-04 |
| KR20020022768A (ko) | 2002-03-27 |
| CA2378661A1 (en) | 2001-01-18 |
| DE60040289D1 (de) | 2008-10-30 |
| CN100402651C (zh) | 2008-07-16 |
| MXPA01013302A (es) | 2004-03-10 |
| ES2312347T3 (es) | 2009-03-01 |
| EP2019140A2 (en) | 2009-01-28 |
| JP2003504064A (ja) | 2003-02-04 |
| ATE408693T1 (de) | 2008-10-15 |
| EP2019140A3 (en) | 2009-02-04 |
| WO2001004320A1 (en) | 2001-01-18 |
| JP4813711B2 (ja) | 2011-11-09 |
| IL147167A (en) | 2010-06-16 |
| IL147167A0 (en) | 2002-08-14 |
| KR100940776B1 (ko) | 2010-02-11 |
| CN1369011A (zh) | 2002-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4795597B2 (ja) | パラインフルエンザウィルス（ｐｉｖ）及びヒトの病原体により引き起こされる感染及び疾病を保護するためへの組換えｐｉｖのベクターとしての使用 | |
| CN100491531C (zh) | 通过缺失或消除非必需基因而减毒的重组副流感病毒疫苗 | |
| CN100402651C (zh) | 减毒的人-牛嵌合副流感病毒(piv)疫苗 | |
| AU2009202359A1 (en) | Recovery of recombinant human parainfluenza virus type 1 (HPIV1) from cDNA use of recombinant HPIV1 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens | |
| EP1572947B1 (en) | RECOVERY OF RECOMBINANT HUMAN PARAINFLUENZA VIRUS TYPE 2 (HPIV2) FROM cDNA AND USE OF RECOMBINANT HPIV2 IN IMMUNOGENIC COMPOSITIONS AND AS VECTORS TO ELICIT IMMUNE RESPONSES AGAINST PIV AND OTHER HUMAN PATHOGENS | |
| US7622123B2 (en) | Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines | |
| US7201907B1 (en) | Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines | |
| US7632508B2 (en) | Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines | |
| US7314631B1 (en) | Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV) | |
| WO2002002605A2 (en) | Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines | |
| AU783189B2 (en) | Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090325 |